Stichting Hemato-oncologie Voor Volwassenen Nederland
Clinical trials sponsored by Stichting Hemato-oncologie Voor Volwassenen Nederland, explained in plain language.
-
Second chance: new combo targets CLL relapse after First-Line venetoclax
Disease control Recruiting nowThis study tests a new two-drug combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) whose cancer returned after initial treatment with venetoclax and an antibody. The goal is to see if this combo can make the cancer undetectable in the b…
Phase: PHASE2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 02, 2026 04:29 UTC
-
New pill targets leukemia's genetic weak spot in landmark trial
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug bleximenib to standard chemotherapy improves outcomes for adults with newly diagnosed acute myeloid leukemia (AML) that has a KMT2A rearrangement or NPM1 mutation. Bleximenib blocks a protein interaction that helps leu…
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated May 01, 2026 16:01 UTC